Get the Stockscreener App
1.40
2.19%
0.03
After Hours:
1.40
Tempest Therapeutics Inc stock is traded at $1.40, with a volume of 216.76K.
It is up +2.19% in the last 24 hours and up +8.53% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$1.37
Open:
$1.36
24h Volume:
216.76K
Relative Volume:
0.09
Market Cap:
$35.16M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-0.5882
EPS:
-2.38
Net Cash Flow:
$-28.18M
1W Performance:
+7.69%
1M Performance:
+8.53%
6M Performance:
-64.19%
1Y Performance:
+359.47%
1-Day Range:
$1.36
$1.45
1-Week Range:
$1.25
$1.45
52-Week Range:
$0.17
$9.77
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Tempest Therapeutics Inc Stock (TPST) Latest News
Scotiabank initates Tempest Therapeutics Inc (TPST) rating to a Sector outperform - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Tempest Therapeutics Inc (TPST) - The Dwinnex
Sigourney Weaver to star in Jamie Lloyd's 'The Tempest' this fall - LondonTheatre.co.uk
A Closer Look at Tempus AI Inc. (TEM) Stock Gains - The InvestChronicle
The Tempest cast announced to join Sigourney Weaver at the Theatre Royal Drury Lane in London - WestEndTheatre.com
See Who's Joining Sigourney Weaver in West End The Tempest - Playbill
Davidson Kempner Capital Management LP Acquires New Shares in Tempus AI, Inc. (NASDAQ:TEM) - MarketBeat
Full Cast Announced for The Tempest at Theatre Royal Drury Lane - London Theatre 1
Gavin & Stacey star joins Sigourney Weaver in The Tempest - RadioTimes
The Tempest with Sigourney Weaver at Theatre Royal Drury Lane announces complete casting - WhatsOnStage.com
Full cast announced for Jamie Lloyd Company’s THE TEMPEST at Theatre Royal Drury Lane - West End Best Friend
Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $45.56 - MarketBeat
Tempus AI (NASDAQ:TEM) Shares Gap Up to $50.09 - Defense World
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Tempus AI (NASDAQ:TEM) Shares Down 5.3% - Defense World
Deeper Dive: Understanding Tempus AI Inc. (TEM) Through its Various Ratios - The Dwinnex
Just the Facts: Tempest Minerals begins fieldwork at Five Wheel Project - Proactive Investors UK
Tempus AI Inc. [TEM] Investment Guide: What You Need to Know - Knox Daily
Keeping an Eye on Tempest Therapeutics Inc (TPST) After Insider Trading Activity - Knox Daily
An analyst sees good growth prospects for Tempus AI Inc. (TEM) - SETE News
Tempest Further Strengthens Leadership Team with - GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs - StockTitan
Tempest Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
An Analysis of Tempest Therapeutics Inc (TPST)’s Potential Price Growth - Knox Daily
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Tempest Therapeutics Inc [TPST] Records 200-Day SMA of $3.1810 - Knox Daily
Is Tempest Therapeutics Inc (TPST) worth investing in despite its undervalued state? - US Post News
Scotiabank initates Tempest Therapeutics Inc (TPST) stock to a Sector outperform - Knox Daily
Anchoring Your Portfolio: Is TPST Stock a Safe Harbor? - The InvestChronicle
Ratios Uncovered: Breaking Down Tempest Therapeutics Inc (TPST)’s Trailing Twelve Months Metrics - The Dwinnex
You might want to take a look at Tempest Therapeutics Inc (TPST) now - SETE News
The Attractiveness of Investing In Tempest Therapeutics Inc (TPST) is Growing - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Tempest Therapeutics Inc (TPST)’s Performance - The Dwinnex
How To Buy Tempest Therapeutics Inc. Stock Online in August 2024 - Traders Union
Should investors be concerned about Tempest Therapeutics Inc (TPST)? - US Post News
TPST’s 2023 Market Dance: Down -67.73% – Time to Invest? - The InvestChronicle
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Tempest Therapeutics Inc [TPST] Owner makes an insider purchase of 387,999 shares worth 0.43 million. - Knox Daily
Tempest Therapeutics appoints new VP of Quality Assurance - Investing.com
Check out these key findings about Tempest Therapeutics Inc (TPST) - SETE News
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance - GlobeNewswire
Market Momentum Report: Tempest Therapeutics Inc (TPST)’s Positive Close at 1.46 - The Dwinnex
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance - StockTitan
Tempest Therapeutics Inc [TPST] Investment Guide: What You Need to Know - Knoxdaily.com
How should investors view Tempest Therapeutics Inc (TPST)? - US Post News
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? - MSN
Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright - Defense World
Tempest Therapeutics Inc [TPST] Shares Rise 30.25% on Thursday - Knox Daily
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):